Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives (opens original article in a new tab)

Fulcrum Therapeutics laid off 85% of its workforce and ended its sickle cell drug program as it looks for a merger or acquisition.

• Fulcrum Therapeutics laid off 85% of its workforce
• Fulcrum Therapeutics ended its sickle cell drug program
• Fulcrum Therapeutics is seeking a merger or acquisition